Nothing Special   »   [go: up one dir, main page]

FR2775187B1 - Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo - Google Patents

Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo

Info

Publication number
FR2775187B1
FR2775187B1 FR9901903A FR9901903A FR2775187B1 FR 2775187 B1 FR2775187 B1 FR 2775187B1 FR 9901903 A FR9901903 A FR 9901903A FR 9901903 A FR9901903 A FR 9901903A FR 2775187 B1 FR2775187 B1 FR 2775187B1
Authority
FR
France
Prior art keywords
epothilone
antiproliferative
manufacture
composition
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9901903A
Other languages
English (en)
Other versions
FR2775187A1 (fr
Inventor
Terence O'reilly
Markus Wartmann
Manuel Litchman
Pamela Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2775187A1 publication Critical patent/FR2775187A1/fr
Application granted granted Critical
Publication of FR2775187B1 publication Critical patent/FR2775187B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR9901903A 1998-02-25 1999-02-16 Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo Expired - Fee Related FR2775187B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Publications (2)

Publication Number Publication Date
FR2775187A1 FR2775187A1 (fr) 1999-08-27
FR2775187B1 true FR2775187B1 (fr) 2003-02-21

Family

ID=27517450

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9901903A Expired - Fee Related FR2775187B1 (fr) 1998-02-25 1999-02-16 Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo

Country Status (10)

Country Link
US (4) US6635666B2 (fr)
EP (1) EP1056453B1 (fr)
JP (1) JP2002504511A (fr)
AU (1) AU755944B2 (fr)
BE (1) BE1011980A5 (fr)
CA (1) CA2319752A1 (fr)
FR (1) FR2775187B1 (fr)
IT (1) ITMI990375A1 (fr)
NZ (1) NZ506187A (fr)
WO (1) WO1999043320A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59610943D1 (de) 1995-11-17 2004-04-22 Biotechnolog Forschung Gmbh Epothilon-Derivate, ihre Herstellung und Verwendung
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) エポチロンc,d,e及びf、製造と薬剤
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (fr) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2000050022A2 (fr) * 1999-02-26 2000-08-31 Napro Biotherapeutics, Inc. Regime de traitement pour les cancers hormonodependants
EP1154779A2 (fr) * 1999-02-26 2001-11-21 Napro Biotherapeutics, Inc. Regime de traitement du cancer de la prostate
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN100341505C (zh) 2001-01-25 2007-10-10 布里斯托尔-迈尔斯斯奎布公司 用于治疗癌症的埃博霉素类似物的给药方法
WO2002058699A1 (fr) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Formes pharmaceutiques d'epothilones pour administration orale
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
WO2002062338A1 (fr) * 2001-01-25 2002-08-15 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
WO2002066033A1 (fr) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Derives d'epothilone destines au traitement de tumeurs refractaires
JP2004522774A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ スクイブ カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
IL157443A0 (en) 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
CA2449077A1 (fr) 2001-06-01 2002-12-12 Gregory D. Vite Derives d'epothilone
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
MXPA04006822A (es) 2002-01-14 2004-12-08 Novartis Ag Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CN102532120A (zh) * 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2439995T3 (es) 2002-09-23 2014-01-27 Bristol-Myers Squibb Company Procedimientos de preparación, aislamiento y purificación de epotilona B
WO2004032923A1 (fr) * 2002-10-11 2004-04-22 Dana-Farber Cancer Institute Inc Derives epothilone pour le traitement du myelome multiple
AU2003293796A1 (en) * 2002-12-09 2004-06-30 Novartis Ag Microtubule stabilisers for treating stenosis in stents
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
JP2009513486A (ja) * 2003-06-27 2009-04-02 ノバルティス アクチエンゲゼルシャフト エポチロンでの癌処置
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
EP1640004A1 (fr) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Utilisation des epothilones pour le traitement des metastases osseuses ou du cancer des os
WO2006055740A1 (fr) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Bille a enrobage enterique comprenant de l’ixabepilone et son procede de preparation
WO2006055742A1 (fr) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
MX2008012717A (es) * 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
CA2669696A1 (fr) * 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Peptides maml stabilises et leurs utilisations
US20100173718A1 (en) 2007-06-20 2010-07-08 Saluc Technologies S.A. Convertible dining / billiard table
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
WO2014116594A1 (fr) * 2013-01-23 2014-07-31 The University Of Toledo Agents anticancéreux hautement sélectifs ciblant le cancer de poumon non à petites cellules et d'autres formes de cancer
WO2017004548A1 (fr) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US253697A (en) * 1882-02-14 John halley and alexandee baee
US127432A (en) * 1872-06-04 Improvement in tuckers for sewing-machines
US87634A (en) * 1869-03-09 Improvement in grain-storehouses
US203876A (en) * 1878-05-21 Improvement in piston water-meters
US220295A (en) * 1879-10-07 Improvement in hinges
US142990A (en) * 1873-09-23 Improvement in machines for burnishing the shanks of boots and shoes
US203938A (en) * 1878-05-21 Improvement in wire fences
US260098A (en) * 1882-06-27 Rolls for longitudinally slitting railroad-rails
US34452A (en) * 1862-02-18 Improvement in railroad joints or chairs
US176429A (en) * 1876-04-25 Improvement in nut-locks
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ATE151767T1 (de) * 1993-07-15 1997-05-15 Pfizer Amid-derivate von 16-gliedrige heterocyclen als antibiotische macrolide
DE59610943D1 (de) * 1995-11-17 2004-04-22 Biotechnolog Forschung Gmbh Epothilon-Derivate, ihre Herstellung und Verwendung
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) エポチロンc,d,e及びf、製造と薬剤
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (fr) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6348551B1 (en) * 1997-04-18 2002-02-19 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CA2299608A1 (fr) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique
SI1052974T1 (sl) 1998-02-05 2009-10-31 Novartis Ag Farmacevtska formulacija, ki vsebuje epotilon
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6121029A (en) * 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
NZ508326A (en) 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
WO2000000485A1 (fr) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Derives d'epothilone, leur procede de production, produits intermediaires et leur utilisation pharmaceutique
DE19848306A1 (de) * 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
DE60114865T2 (de) 2000-04-28 2006-07-27 Kosan Biosciences, Inc., Hayward Heterologe herstellung von polyketiden
WO2005085209A1 (fr) * 2004-03-10 2005-09-15 Kureha Corporation Composé aminé basique et son usage

Also Published As

Publication number Publication date
BE1011980A5 (fr) 2000-03-07
EP1056453B1 (fr) 2010-10-06
EP1056453A1 (fr) 2000-12-06
JP2002504511A (ja) 2002-02-12
US7091226B2 (en) 2006-08-15
WO1999043320A1 (fr) 1999-09-02
US20040024033A1 (en) 2004-02-05
US20020028839A1 (en) 2002-03-07
FR2775187A1 (fr) 1999-08-27
US20060223867A1 (en) 2006-10-05
NZ506187A (en) 2003-11-28
US7875601B2 (en) 2011-01-25
US20050165071A1 (en) 2005-07-28
CA2319752A1 (fr) 1999-09-02
US6635666B2 (en) 2003-10-21
AU755944B2 (en) 2003-01-02
ITMI990375A1 (it) 1999-08-25
AU2927999A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
FR2775187B1 (fr) Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR2733684B1 (fr) Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
FR2780281B1 (fr) Compositions comprenant des nanopigments d'oxydes de fer pour la coloration artificielle de la peau et utilisations
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
FR2765801B1 (fr) Utilisation de monoesters d'arbutine comme agent depigmentant
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
FR2708201B1 (fr) Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
FR2722681B1 (fr) Calecon pour homme
FR2781148B1 (fr) Composition cosmetique comprenant des pigments et un agent antitranspirant, utilisation d'une telle composition
FR2728783B1 (fr) Prothese d'articulation metatarso-phalangienne totale du premier rayon du pied
EE200900049A (et) Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
MD283F1 (ro) Compozitie de ingrediente pentru balsamul tonifiant "legenda"
FR2780427B1 (fr) Poutre mixte bois-beton pour la construction et l'ouvrage d'art
FR2643643B1 (fr) Compositions utilisables pour la preparation de membranes d'etancheite et membranes obtenues
FR2818907B1 (fr) Utilisation de la brivudine pour la preparation d'une composition pharmaceutique
FR2750046B1 (fr) Compositions sous forme d'un gel aqueux comprenant un ceramide ou un compose de type ceramide
FR2746012B1 (fr) Utilisation de la tiamuline pour la preparation d'un medicament comme agent de reversion de la multichimioresistance cancereuse
FR2792833B1 (fr) Utilisation de l'acide n-anisoyl-gamma-aminobutyrique ou de l'acide p-anisique pour la preparation d'une composition pharmaceutique
FR2722688B1 (fr) Utilisation d'un extrait de la plante commiphoramukul comme agent pigmentant ou de culture de melanometique ou pharmaceutique, ou pour la culture des cytes; ou pour la fabrication d'une compostion cosmelanocytes
FR2722991B1 (fr) Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante
FR2800639B1 (fr) Catalyseur bimetallique comprenant du fluor et son utilisation pour l'hydrogenation des composes aromatiques en presence de composes soufres

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20141031